Group 1 - Tempus AI, Inc. (NASDAQ:TEM) is recognized as one of the top 10 stock picks for 2026 by ARK Invest [1] - The company announced a strategic partnership with Merck to accelerate the development of AI-driven precision medicine, particularly in oncology [1][3] - Merck will utilize Tempus's de-identified data and technologies to enhance the discovery and development of candidate therapies [2][3] Group 2 - Following the Q4 earnings call, JPMorgan analyst Casey Woodring reduced the stock's price target from $80 to $60, maintaining a Neutral rating due to concerns over data visibility and outlook revisions [2][3] - As of March 4, the stock is rated as a Moderate Buy with an average upside potential of 52.5% [4] - The healthcare technology company focuses on using artificial intelligence to advance precision medicine [4]